United Therapeutics (United Therapeutics) Price-to-Operating-Cash-Flow

: 12.04 (As of Today)

View and export this data going back to 1999. Start your Free Trial

As of today (2024-04-19), United Therapeutics's share price is $237.04. United Therapeutics's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was $19.68. Hence, United Therapeutics's Price-to-Operating-Cash-Flow Ratio for today is 12.04.

The historical rank and industry rank for United Therapeutics's Price-to-Operating-Cash-Flow or its related term are showing as below:

UTHR' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 6.16 Med: 12.15 Max: 25.41
Current: 12.04

During the past 13 years, United Therapeutics's highest Price-to-Operating-Cash-Flow Ratio was 25.41. The lowest was 6.16. And the median was 12.15.

UTHR's Price-to-Operating-Cash-Flow is ranked better than
75.62% of 283 companies
in the Biotechnology industry
Industry Median: 24.39 vs UTHR: 12.04

United Therapeutics's Cash Flow from Operations per share for the three months ended in Dec. 2023 was $3.01. Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was $19.68.

During the past 12 months, the average Operating Cash Flow per Share Growth Rate of United Therapeutics was 18.90% per year. During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 5.10% per year.

During the past 13 years, United Therapeutics's highest 3-Year average Operating Cash Flow per Share Growth Rate was 50.60% per year. The lowest was -18.50% per year. And the median was 18.50% per year.

United Therapeutics Price-to-Operating-Cash-Flow Historical Data

The historical data trend for United Therapeutics's Price-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

United Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Price-to-Operating-Cash-Flow

8.96

17.09

16.81

11.17

United Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Price-to-Operating-Cash-Flow																16.81	12.37	12.54	11.72	11.17

Competitive Comparison

For the Biotechnology subindustry, United Therapeutics's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

United Therapeutics Price-to-Operating-Cash-Flow Distribution

For the Biotechnology industry and Healthcare sector, United Therapeutics's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where United Therapeutics's Price-to-Operating-Cash-Flow falls into.

United Therapeutics Price-to-Operating-Cash-Flow Calculation

United Therapeutics's Price-to-Operating-Cash-Flow ratio for today is calculated as

Price-to-Operating-Cash-Flow Ratio	=	Share Price	/	Cash Flow from Operations per share (TTM)
	=	237.04	/	19.683
	=	12.04

United Therapeutics's Share Price of today is $237.04.
United Therapeutics's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $19.68.

Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).

It can also be calculated from the numbers for the whole company:

Price-to-Operating-Cash-Flow Ratio

Market Cap

Cash Flow from Operations

United Therapeutics Price-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of United Therapeutics's Price-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.

United Therapeutics (United Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » United Therapeutics Corp (NAS:UTHR) » Definitions » Price-to-Operating-Cash-Flow

Comparable Companies

Traded in Other Exchanges

UTH:Germany

Address

1040 Spring Street, Silver Spring, MD, USA, 20910

Website

https://www.unither.com

United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.

Executives

Paul A Mahon	officer: EVP & General Counsel
Nilda Mesa	director	C/O UNITED THERAPEUTICS CORPORATION, 1040 SPRING STREET, SILVER SPRING MD 20910
Christopher Causey	director
Martine A Rothblatt	director, officer: Chief Executive Officer
Louis W Sullivan	director
Judy D. Olian	director	2000 AVENUE OF THE STARS 12TH FL, LOS ANGELES CA 90067
Michael Benkowitz	officer: President and COO	C/O UNITED THERAPEUTICS CORP, 1040 SPRING STREET, SILVER SPRING MD 20910
Christopher Patusky	director
Raymond Dwek	director
Linda Maxwell	director	1040 SPRING STREET, SILVER SPRING NC 27709
Tommy G Thompson	director	7711 CARONDELET, ST. LOUIS MO 63105
Katherine J Klein	director	STEINBERG HALL-DIETRICH HALL, 3620 LOCUST WALK, PHILADELPHIA PA 19104
Richard Giltner	director	C/O UNITED THERAPEUTICS CORPORTION, 1735 CONNECTICUT AVE. NW, WASHINGTON DC 20009
Roger Jeffs	director, officer: President and COO
David Zaccardelli	officer: EVP & Chief Operating Officer	300 TRI STATE INTERNATIONAL, SUITE 272, LINCOLNSHIRE IL 60069